and intravesicular parenteral formulations are typically aqueous solutions which may contain excipients such as salts carbohydrates and buffering agents preferably to a ph of from 3 to 9 but for some applications they may be more suitably formulated as a sterile non aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile pyrogen free water the preparation of parenteral formulations under sterile conditions for example by lyophilisation may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art idarubicin may be used according to the present invention to treat canine lymphomas the dose of idarubicin to be administered will be determined by the veterinarian taking into account the size of the dog the progression of the disease and any other relevant factors typically the dose of idarubicin may be between 0 4 and 1 0 mg kg when given orally to dogs weighing less than 15 kg and between 9 and 25 mg meter squared to dogs weighing greater than or equal to 15 kg unit dosage forms tablets or capsules providing doses of 0 5 mg 1 mg 5 mg 10 mg and 25 mg allow for the convenient treatment of most breeds of dog the dose may be repeated at suitable intervals such as for example once a week once every two weeks once every three weeks or once a month until the desired outcome is achieved it is possible that idarubicin will be.